Bellicum’s $69 Million Public Offering

Cooley advised Bellicum Pharmaceuticals on its $69 million public offering of 5,750,000 shares of common stock, including the exercise by the underwriters of their option to purchase up to 750,000 additional shares.

Citigroup and Jefferies acted as joint book-running managers for the offering. Guggenheim Securities, Ladenburg Thalmann, Raymond James and SunTrust Robinson Humphrey acted as co-managers.

Bellicum, which trades on The NASDAQ Global Market as “BLCM,” is a clinical-stage biopharmaceutical company focused on developing novel cellular immunotherapies for certain cancers and orphan inherited blood disorders.

Cooley has advised with a team including Julie Robinson (Picture), Karen Deschaine, Phillip McGill, John Ross and Alla Kagan.

Involved fees earner: Julie Robinson – Cooley LLP; Karen Deschaine – Cooley LLP; Phillip McGill – Cooley LLP; John Ross – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Bellicum Pharmaceuticals, Inc.;


Author: Ambrogio Visconti